Citadel Advisors
KPRX icon

Citadel Advisors’s Kiora Pharmaceuticals KPRX Stock Holding History

Citadel Advisors’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95.6K Buy
49,533
+27,152
+121% +$57.3K ﹤0.01% 12053
2025
Q4 		$44.1K Sell
22,381
-22,192
-50% -$50.6K ﹤0.01% 12088
2025
Q3 		$125K Buy
+44,573
New +$122K ﹤0.01% 11677
2025
Q2 		– Sell
-26,550
Closed -$79.9K – 13900
2025
Q1 		$79.9K Buy
+26,550
New +$92.2K ﹤0.01% 11763
2024
Q4 		– Sell
-10,114
Closed -$37K – 14975
2024
Q3 		$37K Buy
+10,114
New +$39.5K ﹤0.01% 12237
2024
Q1 		– Sell
-10,287
Closed -$49.1K – 15065
2023
Q4 		$49.1K Buy
+10,287
New +$53.4K ﹤0.01% 11797
2023
Q2 		– Sell
-1,570
Closed -$47.2K – 14827
2023
Q1 		$47.2K Buy
+1,570
New +$58.7K ﹤0.01% 12232
2022
Q3 		– Sell
-129
Closed -$22K – 13145
2022
Q2 		$22K Buy
+129
New +$21.6K ﹤0.01% 12362
2021
Q3 		– Sell
-59
Closed -$77K – 14266
2021
Q2 		$77K Buy
59
+3
+5% +$4.66K ﹤0.01% 13100
2021
Q1 		$100K Buy
+56
New +$122K ﹤0.01% 12473
2019
Q1 		– Sell
-9
Closed -$22K – 9608
2018
Q4 		$22K Buy
9
+2
+29% +$4.62K ﹤0.01% 8706
2018
Q3 		$11K Buy
7
+2
+40% +$5.37K ﹤0.01% 9103
2018
Q2 		$14K Sell
5
-5
-50% -$14.1K ﹤0.01% 8698
2018
Q1 		$22K Buy
10
+4
+67% +$17.3K ﹤0.01% 8105
2017
Q4 		$34K Buy
+6
New +$37.1K ﹤0.01% 7741

Other funds holding KPRX

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's KPRX Position: Q1 2026 in Review

Citadel Advisors increased its Kiora Pharmaceuticals (KPRX) stake by 121% in Q1 2026, buying an estimated $57.3K and bringing the position to 49,533 shares worth $95.6K. The position accounts for ﹤0.01% of the portfolio, ranked #12053.

Citadel Advisors first reported a position in KPRX in Q4 2017 and has held it in 15 quarters since. The position peaked at $125K in Q3 2025. 18 funds tracked by Wall St. Rank hold KPRX as of Q1 2026.

  • Citadel Advisors held 49,533 shares of Kiora Pharmaceuticals worth $95.6K as of Q1 2026.
  • Citadel Advisors bought 27,152 Kiora Pharmaceuticals shares in Q1 2026, an estimated $57.3K.
  • Kiora Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12053 holding.
  • Citadel Advisors first reported a position in Kiora Pharmaceuticals in Q4 2017 and has held it in 15 quarters since.
  • Citadel Advisors's Kiora Pharmaceuticals position peaked at $125K in Q3 2025.
  • 18 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.